These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22864536)

  • 1. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
    Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
    Support Care Cancer; 2013 Feb; 21(2):549-55. PubMed ID: 22864536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
    Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
    Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
    Strasser F; Demmer R; Böhme C; Schmitz SF; Thuerlimann B; Cerny T; Gillessen S
    Oncologist; 2008 Mar; 13(3):337-46. PubMed ID: 18378545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on taxane development: new analogs and new formulations.
    Yared JA; Tkaczuk KH
    Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and docetaxel in the treatment of breast cancer.
    Saloustros E; Mavroudis D; Georgoulias V
    Expert Opin Pharmacother; 2008 Oct; 9(15):2603-16. PubMed ID: 18803448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
    Schwartzberg LS; Cobb P; Walker MS; Stepanski EJ; Houts AC
    Support Care Cancer; 2009 Aug; 17(8):1081-8. PubMed ID: 19148686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
    Bellon JR; Lindsley KL; Ellis GK; Gralow JR; Livingston RB; Austin Seymour MM
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):393-7. PubMed ID: 10974452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
    Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
    Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
    Schneeweiss A; Lenz F; Beldermann F; Geberth M; Goerner R; Solomayer E; Bastert G
    Zentralbl Gynakol; 2001 Sep; 123(9):520-8. PubMed ID: 11709745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxanes in elderly breast cancer patients.
    Wildiers H; Paridaens R
    Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
    Langer-Nitsche C; Lück HJ; Heilmann M
    Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.